Inve India ▾

Jagsonpal Pharmaceuticals share price & results

Jagsonpal Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Asset-light Indian pharma firm selling niche Gynaecology, Orthopaedics, Dermatology & Paediatric brands.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue82.0 ₹ crore+7.9% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit13.0 ₹ crore+18.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.43 %+2.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin16.32 %−17.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)3.17 %−22.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 5 judged targets kept · 9 open · verdicts reflect calls analysed to Q1 FY27.

Jagsonpal Pharmaceuticals Limited management guidance track record on Inve: 14 targets tracked across analysed earnings calls (2 achieved, 3 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
Capital Allocation StrategyIf cash is not used for inorganic strategy, it will be returned to shareholders.
Call transcript, Q1 FY26 · 28 Jul 2025		Q1 FY26Q1 FY27:This promise pertained to FY26 and was concluded with an 'achieved' verdict. The company has since completed the buyback and made an acquisition.
Call transcript, Q1 FY27 · 30 Jul 2026		Achieved
Full Year Revenue GrowthOverall guidance of 15% for the year.
Call transcript, Q1 FY26 · 28 Jul 2025		Q1 FY26Q1 FY27:This promise pertained to FY26 and was concluded with a 'missed' verdict. No new information in this quarter.
Call transcript, Q1 FY27 · 30 Jul 2026		Missed
Forward Revenue Growth1.5x IPM growth (translating to 12-15%) for FY27 and beyond.
Call transcript, Q3 FY26 · 22 Jan 2026		Q3 FY26Q1 FY27:Company's reported primary sales growth was 9% YoY. Management noted the relevant industry benchmark (IPM) grew 11.6%. As 9% is less than 1.5x of 11.6% (17.4%), the company is not currently meeting this target on a primary sales basis, despite outperformance on a secondary sales (Pharmarack) basis.
Call transcript, Q1 FY27 · 30 Jul 2026		At Risk

Source: Inve Guidance Tracker for Jagsonpal Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Jagsonpal Pharmaceuticals Limited's 14 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹223.11 +0.02% · +₹0.05

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +3.5% 1Y

₹160₹180₹200₹220₹240Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 22 Jan 2026Q4 FY26 — 28 Apr 2026Q1 FY27 — 30 Jul 2026

1Y: ₹215.59 on 24 Oct 2025 → ₹223.11. High ₹243.97 (24 Sept 2026), low ₹161.07 (29 Jan 2026).

Previous close
₹223.06
Market cap
₹1.5k Cr
52-week range
₹161.07 – ₹243.97
One year
+3.46%
Price to earnings (TTM to Jun 2026)
31.01×
Return on equity (TTM to Jun 2026)
18.43%

Overview

Symbol
NSE:JAGSNPHARM
Exchange
NSE
Currency
INR

What Jagsonpal Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Jagsonpal Pharmaceuticals is an India-focused branded pharmaceutical company that markets niche, sub-chronic prescription and OTC brands in Gynaecology, Orthopaedics, Dermatology and Paediatrics/Child-care. It runs an asset-light model, outsourcing manufacturing to WHO-GMP and ISO 9001:2015 certified contract manufacturers (CMOs) and R&D to CDMO partners, while it focuses on brand-building, doctor engagement and distribution. Its brands are pushed through a field force of medical representatives calling on gynaecologists, orthopaedists, paediatricians and dermatologists, backed by a pan-India distributor, stockist and stocking-point network. In 2024 it acquired Yash Pharma's India and Bhutan business, adding brands in Dermatology and Paediatrics and widening its geographic and doctor-reach footprint.

Segments

  • Gynaecology
  • Orthopaedics
  • Dermatology
  • Paediatrics / Child-care
Brand portfolio
33+ established brands, including 20+ ranked Top 5 in their molecule category
Products
75+
Core therapy areas
Gynaecology, Orthopaedics, Dermatology, Paediatrics/Child-care
Medical representative field force
~1,000
Geographic reach
4,000+ towns and cities across India
Distributor network
1,200+ distributors
Founded 1964Headquarters Delhi, India Company website

How the price took the results

close before → close after

Q1 FY27
+2.4%
30 Jul
Q4 FY26
+0.9%
28 Apr
Q3 FY26
+0.5%
22 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Jagsonpal Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Jagsonpal Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Jagsonpal Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.